DOYLESTOWN, Pa., March 05, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced four poster presentations at the American Association of Cancer Research (AACR) Annual Meeting, to take place April 5 to 10, 2024 in San Diego, CA. The posters will cover ATRN-119, Aprea's novel macrocyclic ATR inhibitor, and APR-1051, its next generation inhibitor of WEE1 kinase.
Presentation Details | |
Title: | First-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors harboring cancer-associated gene alterations |
Presenter | Nadeem Q. Mirza, MD, MPH |
Session Title: | First-in-Human Phase I Clinical Trials 2 |
Date and Time: | Tuesday Apr 9, 9:00 AM - 12:30 PM PT |
Location: | Poster Section 48 |
Poster Board Number: | 23 |
Abstract Presentation Number: | CT195 |
Title: | First-in-human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors |
Presenter | Nadeem Q. Mirza, MD, MPH |
Session Title: | First-in-Human Phase I Clinical Trials 2 |
Date and Time: | Tuesday Apr 9, 9:00 AM - 12:30 PM PT |